
Qualigen Therapeutics successfully closed a $41 million PIPE (Private Investment in Public Equity) financing round. Faraday Future Intelligent Electric led the round, marking a pivotal milestone in Qualigen’s strategic growth. The capital raised will drive the company’s bold entry into Web3 and cryptocurrency technologies.
This round marks a significant milestone for Qualigen Therapeutics as it aims to diversify its business model and tap into the rapidly expanding market for decentralized technologies and digital assets.
Two primary investors played central roles in this round. Faraday Future invested $30 million, acquiring a controlling 55% stake in Qualigen Therapeutics. This move highlights the project’s strategic value for Faraday Future and its commitment to actively developing the cryptocurrency business.
Additionally, Jia Yueting, founder and Global Co-CEO of Faraday Future, personally invested $4 million, securing a 7% stake. His personal commitment reflects his strong confidence in the project’s future and his willingness to take direct responsibility for the company’s success.
The funds will power Qualigen’s large-scale expansion into cryptocurrency technologies and blockchain solutions. The company will focus on developing several core products and technologies.
A top priority is launching the C10 Value Anchor System, an innovative mechanism for stabilizing digital asset values. Simultaneously, Qualigen is developing DeAI (Decentralized Artificial Intelligence) smart agents to leverage AI within decentralized environments.
As part of its strategic transformation, Qualigen will rebrand as CXC10. The new business model centers on three main growth drivers and encompasses a portfolio of six flagship products across the Web3 and cryptocurrency technology ecosystem.
Qualigen Therapeutics and Faraday Future’s strategic partnership includes key changes at the executive level. Koti Meka, currently CFO at Faraday Future, will transition to serve as CFO at Qualigen Therapeutics.
This appointment is designed to tightly integrate the financial strategies of both companies and ensure effective deployment of the new capital. Koti Meka’s expertise in managing finances for technology companies will support Qualigen’s ambitious push into the cryptocurrency and blockchain sectors.
Jia Yueting is a prominent Chinese crypto investor and entrepreneur with deep industry experience. He actively invests in Bitcoin and altcoins, and participates in major crypto projects. His $41 million investment in Qualigen demonstrates his significant influence in the sector.
The funds will accelerate the development of Qualigen’s cryptocurrency business and Web3 ecosystem. The company will rebrand as CXC10 and focus on three primary growth areas in crypto and Web3, leveraging the capital to scale operations and drive innovation.
Qualigen has pivoted from pharmaceutical research to cryptocurrency and Web3 initiatives. The company now concentrates on advancing blockchain technology and decentralized finance solutions within the digital ecosystem.
This round signals growing maturity in the cryptocurrency market. Investors are channeling capital into real economic activity, reflecting increased confidence in cryptocurrencies as part of the broader financial system. The market is evolving from speculation to sustainable growth.
Investments in this space face market volatility and regulatory risks. Crypto projects are subject to policy shifts and market trends. It’s important to conduct thorough due diligence before making investment decisions.
Qualigen stands out in its Web3 strategic transformation, with $41 million in backing. The addition of Co-CEO Jerry Wang and Chief Advisor Jia Yueting delivers robust leadership. The project shows strong growth potential within the crypto sector.











